Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4815 - Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): a retrospective analysis.


11 Sep 2017


Poster display session


Cytotoxic Therapy;  GIST


lorena Incorvaia


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


L. Incorvaia1, G. Badalamenti1, E. Musso1, I. de luca1, A. Casarin1, G.M. Assanto1, A. Galvano1, F. Passiglia1, N. Barraco1, B. Vincenzi2, G. Grignani3, M. Pantaleo4, L. Gatto5, S. Rizzo1, D. Fanale1, M. Castiglia1, A. Guarini1, A. Russo1

Author affiliations

  • 1 Department Of Surgical, Oncological And Oral Sciences, Section Of Medical Oncology, University Of Palermo, Palermo, Italy, AOU Policlinico "Paolo Giaccone", 90127 - Palermo/IT
  • 2 Medical Oncology Unit, Campus Bio-Medico di Roma, 128 - Roma/IT
  • 3 Medical Oncology Unit, IRCCS Istituto di Candiolo, 10060 - Candiolo/IT
  • 4 Medical Oncology Unit, Policlinico S. Orsola-Malpighi, 40138 - Bologna/IT
  • 5 Medical Oncology Unit, policlinico Sant'Orsola Malpighi, bologna/IT


Abstract 4815


Imatinib is currently the standard therapy for first line treatment of metastatic GIST. Although this treatment has demonstrated durable responses with PFS and OS benefit, most patients develop resistance and experience subsequent disease progression. Current treatment available in second line are Imatinib high-dose (800 mg/day) or Sunitinib. The presence of two options in this setting, in the absence of direct comparisons, raises many questions on the choice.


A total of 128 patients with metastatic GIST were collected in our analysis in this large database. We analyzed the validity of several parameters as possible predictors of response to treatment with Imatinib high-dose vs Sunitinib in patients progressing at the standard dose of Imatinib 400 mg/day. The parameters analyzed were: anatomic site of primary GIST, site of metastasis, KIT and PDGFRa mutational status, and FDG-PET status at progressing disease. Every factor has been correlated with Progression Free Survival (PFS) for Imatinib 800 mg/day and Sunitinib treatment, measured in months. Datas collected have been analyzed with software “Medcalc”, performed by using the Kaplan-Meier method.


Univariate analysis showed Sunitinib more active then Imatinib in gastric GISTs (median PFS: Sun 12 months vs Ima 800 6 months; p 


with the limitations of a retrospective analysis, this study identifies the gastric site of primary tumor as a predictive factor to efficacy of Sunitinib treatment in second line. The mutational status (GIST WT), the site of metastasis (peritoneum) and the FDG-PET status (negative), although not statistically significantly, seem to be elements of increased activity for Sunitinib treatment in second line.

Clinical trial identification


Legal entity responsible for the study

University of Palermo




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.